Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Cell reports ; h5-index 119.0

Inactive ingredients and generally recognized as safe compounds are regarded by the US Food and Drug Administration (FDA) as benign for human consumption within specified dose ranges, but a growing body of research has revealed that many inactive ingredients might have unknown biological effects at these concentrations and might alter treatment outcomes. To speed up such discoveries, we apply state-of-the-art machine learning to delineate currently unknown biological effects of inactive ingredients-focusing on P-glycoprotein (P-gp) and uridine diphosphate-glucuronosyltransferase-2B7 (UGT2B7), two proteins that impact the pharmacokinetics of approximately 20% of FDA-approved drugs. Our platform identifies vitamin A palmitate and abietic acid as inhibitors of P-gp and UGT2B7, respectively; in silico, in vitro, ex vivo, and in vivo validations support these interactions. Our predictive framework can elucidate biological effects of commonly consumed chemical matter with implications on food- and excipient-drug interactions and functional drug formulation development.

Reker Daniel, Shi Yunhua, Kirtane Ameya R, Hess Kaitlyn, Zhong Grace J, Crane Evan, Lin Chih-Hsin, Langer Robert, Traverso Giovanni

2020-Mar-17

data science, drug delivery, excipient-drug interactions, food-drug interactions, inactive ingredients, machine learning, pharmacokinetics, pharmacology, virtual screening